Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
NCT ID: NCT00504959
Last Updated: 2016-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
234 participants
INTERVENTIONAL
2007-07-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
NCT00470678
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00331864
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
NCT00251459
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
NCT00284089
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
NCT00749021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ranibizumab
ranibizumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ranibizumab
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis
Role: STUDY_CHAIR
Board of Hacettepe University , Ankara, turkey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigational Site
Melbourne, , Australia
Novartis Investigative Site
Laken, , Belgium
Novartis Investigative Site
Leuven, , Belgium
Novartis Investigative Site
Liège, , Belgium
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Bonn, , Germany
Novartis Investigative Site
Bremen, , Germany
Novartis Investigative Site
Chemnitz, , Germany
Novartis Investigative Site
Cologne, , Germany
Novartis Investigative Site
Düsseldorf, , Germany
Novartis Investigative Site
Kiel, , Germany
Novartis Investigative Site
Leipzig, , Germany
Novartis Investigative Site
Marburg, , Germany
Novartis Investigative Site
München, , Germany
Novartis Investigative Site
Siegburg, , Germany
Novartis Investigative Site
Tübingen, , Germany
Novartis Investigative Site
Würzburg, , Germany
Novartis Investigative Site
Budapest, , Hungary
Novartis Investigative Site
Debrecen, , Hungary
Novartis Investigative Site
Petah Tikva, , Israel
Novartis Investigative Site
Tel Aviv, , Israel
Novartis Investigative Site
Tel Litwinsky, , Israel
Novartis Investigative Site
Amsterdam, , Netherlands
Novartis Investigative Site
Nijmegen, , Netherlands
Novartis Investigative Site
Coimbra, , Portugal
Novartis Investigative Site
Porto, , Portugal
Novartis Investigative Site
Alicante, , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Santiago de Compostela, , Spain
Novartis Investigative Site
Valencia, , Spain
Novartis Investigative SIte
Ankara, , Turkey (Türkiye)
Novartis Investigative Site
Bristol, , United Kingdom
Novartis Investigative Site
Southampton, , United Kingdom
Novartis Investigative Site
West Midlands, , United Kingdom
Novartis Investigative Site
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, Seres A, Gekkieva M, Nieweg A, Pilz S; SECURE Study Group. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013 Jan;120(1):130-9. doi: 10.1016/j.ophtha.2012.07.026. Epub 2012 Sep 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRFB002A2402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.